Compare SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SP Funds S&P 500 Sharia Industry Exclusions ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59.24 (market cap $3.38B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SP Funds S&P 500 Sharia Industry Exclusions ETF for 66 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SPUS | TVTX | |
|---|---|---|
Market Cap | $3.38B | $4.88B |
Volume | 308,295 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $61.15 | $67.52 |
52-Week Low | $46.65 | $26.79 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPUS trades at $60.53, showing minimal daily movement with a slight decline of 0.07%. Technical indicators signal a bullish trend with strong moving average support, though oscillators remain neutral. The ETF maintains regular dividend distributions, with recent payments of $0.03 per share. Short interest saw significant growth in September, increasing 174.5% to 257,142 shares as of September 15, 2026.
The ETF's technical strength supports near-term upside potential, though elevated short interest indicates some bearish sentiment. Dividend consistency provides income appeal, but investors should monitor the growing short position which could increase volatility. The neutral oscillator readings suggest potential consolidation before further directional movement.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
